Intra- and extracellular fluorouracil uptake: Assessment with contrast- enhanced metabolic F-19 MR imaging

Radiology

Volumn 209, Issue 1, 1998, Pages 259-267

  Brix, Gunnar ^a   Bellemann, Matthias E ^a   Gerlach, Ludwig ^a   Haberkorn, Uwe ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Fluorouracil; Gadolinium; Liver neoplasms; Magnetic resonance (MR), contrast agents; Magnetic resonance (MR), nuclei other than H; Neoplasms, experimental; Neoplasms, MR

Indexed keywords

ALPHA FLUORO BETA ALANINE; CONTRAST MEDIUM; FLUORINE; FLUOROURACIL; GADOLINIUM PENTETATE MEGLUMINE; GADOXETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MONITORING; DRUG UPTAKE; INTRACELLULAR TRANSPORT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORRIS HEPATOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHANTOM; PRIORITY JOURNAL; RAT;

EID: 0031661321     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.209.1.9769841     Document Type: Article

References (38)

1. Heidelberger CH, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines: a new class of tumor-inhibitory compounds. Nature 1957; 179:663-666.
2. Kemeny N. Current approaches to metastatic colorectal cancer. Semin Oncol 1994; 21:67-75.
3. Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 1994; 20: 11-49.
4. Heidelberger C. On the rational development of a new drug: the example of the fluorinated pyrimidines. Cancer Treat Rep 1981; 65:3-9.
5. Myers CE. The pharmacology of the fluoropyrimidines. Pharmacol Rev 1981; 33:1-15.
6. 19F NMR. Br J Cancer 1984; 50:113-117.
7. Malet-Martino MC, Martino R, Lopez A, et al. New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR. Cancer Chemother Pharmacol 1984; 13:31-35.
8. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pre-treatment. Cancer Res 1988; 48:1680-1688.
9. 19F MRS studies of fluoropyrimidine chemotherapy: a review. NMR Biomed 1989; 2:133-141.
10. 19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. Cancer Res 1991; 51:1384-1390.
11. 19F nuclear magnetic resonance spectroscopy. Cancer Res 1991; 51:5806-5812.
12. 19F NMR spectroscopy. NMR Biomed 1991; 4:274-278.
13. Sijens PE, Baldwin NJ, Ng TC. Multinuclear MR investigations of the metabolic response of the murine RIF-1 tumor to 5-fluorouracil chemotherapy. Magn Reson Med 1991; 19:373-385.
14. Wolf W, Albright MJ, Silver MS, Weber H, Reichardt U, Sauer R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn Reson Imaging 1987; 5:165-169.
15. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc Natl Acad Sci USA 1990; 87:492-496.
16. 19F magnetic resonance spectroscopy. Br J Radiol 1990; 63:547-553.
17. Semmler W, Bachert-Baumann P, Gückel F, et al. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology 1990; 174:141-145.
18. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 1990; 8:1868-1873.
19. Port RE, Bachert P, Semmler W. Kinetic modeling of in vivo nuclear magnetic resonance spectroscopy data: 5-fluorouracil in liver and liver tumors. Clin Pharmacol Ther 1991; 49:497-505.
20. 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn Reson Imaging 1994; 12:497-511.
21. 19F MRI: a comparative animal study. Nucl Med Biol 1996; 23:897-906.
22. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997; 54:3415-3423.
23. 19F MRS (abstr). In: Proceedings of the Second Meeting of the Society of Magnetic Resonance. Berkeley, Calif: Society of Magnetic Resonance, 1994; 895.
24. 19F MRS study (abstr). In: Proceedings of the Third Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 1995; 1689.
25. Lauffer RB. Magnetic resonance contrast media: principles and progress. Magn Reson Med 1990; 6:65-84.
26. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991; 22:233-237.
27. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183:59-64.
28. Brix G, Bellemann ME, Zabel HJ, Bachert P, Lorenz WJ. Selective F-19 MR imaging of 5-fluorouiacil and α-fluoro-β-alanine. Magn Reson Imaging 1993; 11:1193-1201.
29. 19F MR imaging. Magn Reson Med 1995; 34:302-307.
30. Morris HP. Studies on the development, biochemistry and biology of experimental hepatomas. Adv Cancer Res 1965; 9:227-302.
31. Mezrich R. A perspective on k-space. Radiology 1995; 195:297-315.
32. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47:3039-3051.
33. Jain RK. Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 1991; 60:85-100.
34. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271:58-65.
35. Dimitrakopoulou A, Strauss LG, Clorius JH, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal cancer. J Nucl Med 1993; 34:1075-1081.
36. 18F]fluorouracil positron emission tomography (PET). Eur J Cancer 1993; 29:1682-1686.
37. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50:4417-4422.
38. Bellemann ME, Brix G, Haberkorn U, et al. Fluorine-19 NMR mapping of the novel anticancer drug gemcitabine (2′,2′-difluoro-2′-deoxycytidine) in experimental tumor systems (abstr). In: Proceedings of the Third Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 1995; 1685.